Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay [published erratum appears in Blood 1995 Dec 15;86(12):4710]

摘要: Measurement of P-glycoprotein and the gene that encodes it, mdr-1, is an important tool for assessing impact multidrug resistance in clinical cancer. We evaluated mdr-1 expression by a quantitative polymerase chain reaction (PCR) assay 78 biopsy samples from 48 patients with refractory lymphoma enrolled on trial infusional chemotherapy (EPOCH) which R-verapamil was added as antagonist subset whose tumors were unresponsive to treatment. Expression detectable all biopsies at time enrollment study, fourfold or greater increase mdr- 1 noted 42% treatment failure. also diagnosis lymphoma. An endogenous control gene, beta 2-microglobulin, quantitated normalization values. The use 2-microglobulin validated comparing Northern blots detecting actin, GAPDH expression. Immunoblot analysis suggested no major discrepancy present between mRNA protein level. Immunophenotyping lymphomatous lymph nodes showed infiltration tumor cells ranged 8% 95% normal T 1% 83%. monocytes shown be low. levels patient independent T- cell contamination, suggesting presence has best small measurements. can PCR, wide variations observed. Increased disease supports role Pgp drug These studies will aid design interpretation trials